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ABSTRACT 
Naturally acquired tumor-specific T-cells can be detected in most advanced cancer patients. 
Yet, they often fail to control or eliminate the disease, in contrast to many virus-specific CD8 
T lymphocytes. Therapeutic vaccines aim at inducing and boosting specific T-cells mediated 
immunity to reduce tumor burden. The properties of CD8 T-cells required for protection from 
infectious disease and cancer are only partially characterized.  
 
The objectives of this study were to assess effector functions, stage of differentiation and 
clonotype selection of tumor-reactive T lymphocytes following peptide vaccination in 
melanoma patients over time. Results were compared to protective viral-specific T-cell 
responses found in healthy individuals. We also characterized dominant versus low/non 
dominant T-cell clonotypes with the aim to further understand the in vivo function of each set 
of frequency-based specific T-cells. 
 
Here we developed and applied a novel approach for molecular and functional analysis of 
single T lymphocytes ex vivo. T-cell receptor (TCR) clonotype mapping revealed rapid 
selection and expansion of co-dominant T-cell clonotypes, which made up the majority of the 
highly differentiated “effector” T-cells, but only 25% of the less differentiated “effector-
memory” cells, mostly composed of non-dominant clonotypes. Moreover, we show that 
advanced effector cell differentiation was indeed clonotype-dependent. Surprisingly, however, 
the acquisition of effector functions (cytokine production, killing) was clonotype-independent. 
Vaccination of melanoma patients with native peptide induced competent effector function in 
both dominant and non-dominant clonotypes, suggesting that most if not all clonotypes 
participating in a T-cell response have the potential to develop equal functional competence. 
In contrast, many T-cells remained poorly functional after vaccination with analog peptide, 
despite similar clonotype-dependent differentiation. Our findings show that the type of 
peptide vaccine has a critical influence on the selection and functional activation of the 
clonotypic T-cell repertoire. They also show that systematic assessment of individual T-cells 
identifies the cellular basis of immune responses, contributing to the rational development of 
vaccines. 
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INTRODUCTION 
Protective T-cell responses are characterized by strong initial clonal T-cell bursts arising from 
a relatively small number of highly specific naïve precursor T-cells 1. Analysis of T-cell 
receptor (TCR) repertoires of protective virus-specific CD8 T-cells revealed that up to high 
frequencies of epitope-specific T-cells are composed of small numbers (≈5 to 50) of co-
dominant clonotypes 2, yet having the ability to recognize the same pMHC complex. Along 
with the extraordinary high TCR selectivity, T-cells undergo profound cell activation and 
proliferation, resulting in frequency increase and memory/effector cell differentiation, 
assuring respectively T-cell survival, homing and long-term persistence, and strong effector 
function 3. Among the currently identified correlates of protection, high frequency of naïve 
precursor T-cells, high antigen sensitivity (also defined as functional avidity), cross-reactivity 
to antigenic variants, and poly-functionality (including proficient cytotoxic activity and 
multiple cytokine production) appear essential to achieve best in vivo CD8 T-cell efficacy 4-11. 
Naturally acquired self-antigen (tumor)-specific T-cell responses can be detected in most 
advanced cancer patients. However, they often fail to control or eliminate the disease, in 
contrast to many virus-specific CD8 T-cell responses (reviewed in 12, 13). This likely reflects 
the impact of both central and peripheral tolerance in shaping self antigen-specific T-cell 
repertoires. Therapeutic vaccination against cancer aim of generating and/or boosting 
effective type 1 immune responses (Th1 and CD8 T-cell activation) to destroy tumor cells and 
prevent tumor progression. These goals are similar as for vaccines against viral diseases. 
There is a great need to characterize and determine the biological similarities and differences 
between protective (i.e. EBV- and CMV-specific) and non-protective (i.e. tumor-specific) T-
cells.  
Only limited data is available regarding T-cell clonotypes. Yet, clonotypic analyses provide 
great insight, mostly because T-cell clonotypes can be followed in a straightforward manner 
at any time and body location using the TCR as a clonotypic marker 14, 15. For example, 
combined ex vivo analysis of T-cell differentiation and clonality allowed the identification of 
a naturally primed T-cell clone in a melanoma patient 14. The progeny of this clone dominated 
the CD8 T-cell response to the tumor antigen Melan-A/MART-1 14, similarly to the clonal 
expansions observed in virus-specific T-cell responses 7, 16, 17. However, in these patients and 
healthy individuals, one can also find large numbers of low/(non)-dominant T-cell clonotypes 
among tumor-specific 15 and virus-specific 16 CD8 T-cells. Remarkably, not only the 
dominant, but also the subdominant virus-specific clonotypes are maintained stably over 
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years, keeping the TCR repertoire composition constant 16. These observations raise the 
questions whether dominant T-cell clonotypes are sufficient, or whether low/(non)-dominant 
clonotypes are also functionally competent and required for protection. 
Historically, research has mostly focused on dominant T-cell clonotypes, whereas the in vivo 
functions of non-dominant clonotypes remain poorly characterized, likely because of 
technical limitations. Therefore, we developed novel methods suitable for the ex vivo 
functional assessment of individual T-cells, combined with clonotypic characterization. With 
this strategy, we analyzed tumor-specific T-cells from melanoma patients, in parallel to 
protective EBV- and CMV-specific T-cells. The melanoma patients had received potent low 
dose synthetic vaccines composed of Melan-AMART-126-35 peptide, CpG and Incomplete 
Freund’s Adjuvant (IFA) that consistently induced strong and thus ex vivo detectable T-cell 
responses 18, even when using the weakly antigenic native tumor peptide 19.  
Here, we report the preferential selection and expansion of several tumor-specific co-
dominant clonotypes of intermediate to high frequencies, irrespective of whether native or 
analog peptide was used for vaccination. Similar to EBV-specific T-cell responses 16, these 
clonotypes made up the majority of the differentiated “effector” T-cells, but only 25% of the 
less-differentiated “effector-memory” cells. The latter is mostly composed of non-dominant 
clonotypes, thus demonstrating clonotype-dependent differentiation. Surprisingly, however, 
the acquisition of effector function was clonotype independent, as we found similar functional 
profiles in dominant and low/non-dominant T-cell clonotypes. Finally, effector functions were 
more pronounced after native than analog peptide vaccination. In summary, this study reveals 
that effector functions are determined primarily by antigen and the stage of T-cell 
differentiation, but are similar in all clonotypes participating in a CD8 T-cell response.  
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RESULTS 
Strong expansion and effector cell differentiation of tumor-reactive CD8 T-cells 
following peptide vaccination. Fifteen HLA-A2pos patients with advanced metastatic 
melanoma received monthly vaccinations consisting of either the native Melan-AMART-1 26-35 
unmodified peptide (EAAGIGILTV, i.e. “EAA”) or the analog Melan-AMART-1 A27L 
modified heteroclitic peptide (ELAGIGILTV, i.e. “ELA”), combined with CpG 7909 and 
emulsified in IFA (Fig. 1A). Using fluorescent HLA-A2/peptide multimers for ex vivo 
analysis, high frequencies of Melan-AMART-1 specific CD8 T lymphocytes were detected in all 
patients, and highly increased as compared to before vaccination (defined as time 0; SI Fig. 1 
and 20). Tumor-reactive T-cells exhibited an effector-memory (EM; CD45RAnegCCR7neg, 21) 
phenotype and included two distinct functional subsets based on CD28 expression 14, 15, 22, 23; 
(i) CD28-positive (defined thereafter as EM28pos or early differentiated) cells and (ii) CD28-
negative (EM28neg or effector-like) cells. Apart from a few exceptions (patients LAU 321, 
LAU 672 and LAU 936), we found progressive accumulation of differentiated effector 
EM28neg Melan-A-specific T-cells, which appeared early in some patients and later in others, 
independent of whether patients received native or analog peptide (SI Fig. 1). The established 
T-cells were maintained over extended periods of time while patients continuously received 
monthly booster vaccinations. 
 
Vaccination-induced T-cell responses are characterized by robust selection and 
expansion of particular clonotypes. We characterized in depth the ex vivo TCR repertoire 
diversity and clonal selection of tumor-reactive T-cells in patients vaccinated either with the 
native (EAA; n = 5) or the analog (ELA; n = 10) Melan-A peptide, as described previously 14. 
Primed EM28pos cells displayed large polyclonal TCR repertoires with a diverse usage of the 
22 different BV families studied, and high variability in CDR3 size (SI Fig. 2A). However, 12 
of the 15 patients showed progressive restrictions in TCR BV/CDR3 diversity from EM28pos 
to EM28neg T-cell subsets (Fig. 1B), which was accompanied with a strong increase in 
frequencies of co-dominant T-cell clonotypes found among the latter, more differentiated 
effector-like subset (Fig. 1C; SI Table 2 and SI Fig. 2B), irrespective of native or analog 
peptide used for vaccination. A striking observation was that the T-cell responses were 
dominated by individual clonotypes in several patients (e.g. LAU 618, BV17-1 and BV3-1; 
LAU 672, BV7-1; LAU 972, BV5-1; LAU 1013, BV13-1), in line with our previous report 14. 
Despite that the proportion of non-dominant TCR sequences (termed as BV “other”) was 
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much greater in EM28pos than in EM28neg T-cells, oligoclonal expansions of particular T-cell 
clonotypes were also found in the former subset, representing an average of 25% of the 
repertoire (SI Fig. 2C). Many of the dominant clonotypes identified in the differentiated 
EM28neg subset were also found, though at much lower frequencies, in the EM28pos 
compartment. Interestingly, in native peptide vaccinated patients, common T-cell clonotypes 
were more frequently distributed between both subsets. Altogether, these findings show that 
both clonotype selection and composition of vaccination-induced tumor-reactive T-cell 
responses along cell differentiation resembled closely to those observed for protective EBV-
specific responses 16 (SI Fig. 2C). Yet, the proportion of non-dominant clonotypes was greater 
in vaccination-induced tumor-specific T cells compared to anti-viral responses. 
 
Vaccination with native peptide rapidly induced clonotypes shared between early- and 
late-differentiated T-cell subsets. We next investigated the time course of establishment of 
dominant T-cell clonotypes following vaccination and their persistence over time (Fig. 2). To 
directly assess the presence of particular clonotypes ex vivo and their relative frequencies 
within distinct T-cell subsets, we used a modified RT-PCR protocol, enabling the detection of 
specific cDNAs after global amplification of expressed mRNAs from as few as five sorted T-
cells 14, 24. The unique TCR signature of each clonotype was subsequently determined by 
CDR3 size lengths, clonotype specific primers and/or sequencing of amplified products 
containing the CDR3 region 14. In patients receiving the native peptide (EAA), transcript 
analysis revealed the emergence of dominant clonotypes of intermediate and high frequencies 
as early as 1 to 3 months after the start of vaccination (Fig. 2B and 2C), and this rapid 
selection was already evident within the early-differentiated EM28pos subset (Fig. 2B; SI Fig. 
3A). These findings contrasted with the clonotype kinetics observed in patients vaccinated 
with the analog peptide (ELA), where the T-cell repertoire was largely composed of single 
non-dominant clonotypes. In those patients, most of the dominant T-cell clonotypes appeared 
after 3 months, and thus reached similar frequencies as patients vaccinated with native peptide 
only at later time-points (Fig. 2A and 2C; SI Fig. 3A). We also observed that the number of 
dominant clonotypes shared between EM28pos and EM28neg subsets at early time-points (≤ 3 
months) after vaccination was greatly increased in the native compared to the analog cohort 
(SI Fig. 3B). In line with our previous reports 14, 15, repetitive vaccinations induced in both 
cohorts sustained tumor-specific T-cell responses and the persistence of co-dominant 
clonotypes over several months to years (Fig. 1A). Our data reveal the establishment 
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following therapeutic vaccination of relative few (between 7 to 15) co-dominant tumor-
specific T-cell clonotypes and specific for each patient. We conclude that dominant 
clonotypes from the native peptide vaccination-induced responses appeared earlier and were 
more frequently shared between early- and late-differentiated T-cell subsets. 
 
Enhanced expression of multiple effector mediators by native peptide vaccination-
induced T-cells, closely resembling highly differentiated CMV-specific T-cells. To 
qualitatively assess the effect of native versus analog peptide vaccination, we developed 
techniques for combined ex vivo analysis of molecular and functional properties at the single-
cell level (Fig. 3A and 3B; SI Fig. 4A). We found that most early-differentiated EM28pos T-
cells issued from patients vaccinated with the analog/ELA peptide contained low detectable 
levels of mRNA coding for effector mediators such as IFN-γ, perforin, granzyme B and C-
type killer cell lectin-like receptor CD94, while expressing measurable levels of mRNA 
coding for the costimulatory molecule CD27 and the cytokine receptor IL-7Rα (CD127). 
Increased expression of effector mediators and concomitant down-regulation of costimulatory 
and cytokine receptors was observed within ELA-specific EM28neg differentiated T-cells, 
similarly to the single-cell gene expression profiling depicted by CMV-specific T-cells upon 
cell differentiation. EBV-specific T-cells also presented distinct mRNA expression patterns 
along cellular differentiation, but globally these cells remained less differentiated than tumor- 
or CMV-specific T-cells, in agreement with our recent report 16. A remarkable finding was 
that the tumor-reactive T-cells generated following native peptide vaccination exhibited 
similar detectable levels of effector mediators than those observed in CMV-specific T-cells. 
Importantly, such expression patterns were already found within the EM28pos compartment, 
despite the co-expression of early-differentiated CD27 and IL-7Rα gene transcripts (Fig. 3A 
and 3B). These cells also showed more poly-functional expression profiles compared with the 
corresponding EM28pos T-cells specific for ELA and EBV epitopes (SI Fig. 4B). mRNA 
content correlated with protein expression, as confirmed by extended ex vivo multi-parameter 
flow cytometry analyses of T-cells from all 15 vaccinated melanoma patients as well as 5 
healthy individuals with persistent herpes virus infections (Fig. 4; SI Fig. 5). Thus, native 
peptide vaccination, in contrast to analog peptide, readily induced expression of a 
comprehensive set of functionally key molecules in the early-differentiated EM28pos T-cell 
subset.  
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A hierarchical clustering performed on a total of 529 single-cell samples identified 5 distinct 
clusters based on the differential co-expression patterns of the 6 studied genes (Fig. 3C). The 
Heat-map analysis further allowed determining the repartition of these clusters within the 
single-cell samples of each T-cell subset, showing that antigen-specific T-cells could be 
divided into two major groups/families. The first one was composed of the early-
differentiated EM28pos T-cells specific for the ELA, EBV and CMV epitopes, and included 
the EMRA EBV-specific subset. The second group was formed by the differentiated effector-
like EM28neg/EMRA ELA-, EAA-, and CMV-specific T-cells, and strikingly also comprised 
the early-differentiated EM28pos T-cells induced by the native/EAA peptide. Altogether, our 
results indicate that vaccination with the native but not analog tumor antigen generated CD8 
T-cell responses of enhanced cell activation and poly-functionality in vivo, independently of 
CD28, CD27 and IL-7Rα co-expression, and resembling highly differentiated CMV-specific 
responses.  
 
Both T-cell differentiation and the peptide used for vaccination determine the functional 
profile of individual T-cell clonotypes. The powerful single-cell based approach allowed for 
the first time to analyze in vivo gene expression of (multiple representatives of) individual T-
cell clonotypes. By this strategy, we compared clonotype performance after vaccination with 
analog versus native peptide based on their frequencies. Profiles of dominant T-cell 
clonotypes (Fig. 5A) largely overlapped those observed for the tumor-specific subsets from 
which they were respectively isolated (SI Fig. 4B). For instance, the dominant BV3-1 
clonotype from patient LAU 618/ELA shared the gene expression profile of early-
differentiated EM28pos subsets from analog peptide vaccinated patients. Conversely, the 
profiles of the dominant native peptide vaccination-induced BV13-1 clonotype from patient 
LAU 1013 were highly poly-functional, thus corresponding to the overall gene expression 
profiles found within the respective EM28pos and EM28neg subset. Strikingly, gene expression 
signatures of non-dominant tumor-reactive T-cells (Fig. 5B) correlated also tightly with the 
subset of origin (e.g. EM28pos or EM28neg) and the type of peptide used for vaccination (e.g. 
native or analog peptide). Similar observations were made for the dominant and low/(non)-
dominant clonotypes found in EBV- and CMV-specific immune responses. In summary, we 
found that the functional profile of dominant and low/non-dominant T-cell clonotypes was 
primarily determined by the antigen and the stage of differentiation. 
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Efficient target cell killing by T-cells of both dominant and non-dominant clonotypes 
from patients vaccinated with native peptide. We assessed the ability of native and analog 
peptide vaccination-induced tumor-specific T-cells to recognize and kill Melan-A-expressing 
tumor cells (Fig. 6A and 6B, SI Fig. 6A). As expected, most T-cell clones derived from the 
differentiated effector-like EM28neg subset were able to kill the Melan-A-expressing tumor 
cell line Me 290, irrespectively of the peptide used for vaccination. However, T-cell clones 
derived from the early-differentiated EM28pos subset following analog peptide vaccination 
were often deficient in cytotoxic function. In contrast, a large majority of T-cell clones 
derived from the same EM28pos subset from patients vaccinated with the native peptide 
efficiently killed the Me 290 cell line. Strikingly, this occurred regardless of whether these 
clones were of high (dominant clonotypes) or very low (non-dominant clonotypes) 
frequencies (Fig. 6B). Conclusions with respect to the in vivo status of T-cells are possible 
because these functional results correspond to gene and protein expression data (Fig. 3 and 
Fig. 4). Furthermore, we have previously demonstrated that our T-cell clones maintained their 
in vivo programmed phenotypic and functional properties despite several weeks of in vitro 
culture 25. 
The functional avidity for the pMHC of these clones was determined by cytotoxic assays 
against HLA-A2pos T2 cells in the presence of graded peptide concentrations (Fig. 6C and SI 
Fig. 6B). Native peptide vaccination-induced T-cells derived from EM28pos cells were again 
significantly superior in regards to maximal lysis capacity, compared to the killing responses 
obtained from the corresponding subset upon analog peptide vaccination. As observed for 
tumor cell killing assays, maximal T2 lysis was found for both dominant and non-dominant 
clonotypes issued from native peptide vaccination. Regarding functional avidity (EC50), all 
native and analog peptide-derived EM28pos T-cell clones behaved similarly, with 50% 
maximal lysis of T2 cells found at comparable peptide doses (and no statistically differences). 
Yet, the latter subset showed a high degree of heterogeneity where a substantial fraction of the 
T-cell clones depicted poor to no killing (EC50 > 10-6 M), contrasting with the native peptide 
vaccination-induced clones displaying more homogeneous killing.  
Collectively, these data revealed differential cytotoxicity of analog peptide generated T-cell 
clones depending on the in vivo differentiation stage, and consistent with our previous report 
25. In contrast to analog peptide vaccination, strong cytolytic activity and potent functional 
avidity, regardless of the type of subset (i.e. clones isolated from EM28pos or EM28neg) was 
observed after vaccination with the native peptide. This finding may likely be attributed to the 
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stronger expression of multiple effector molecules found within EM28pos T-cells from native 
versus analog peptide vaccination (Fig. 3 and 4). Importantly, similar efficient target cell 
killing (maximal lysis and EC50) was observed in all dominant and non-dominant T-cell 
clonotypes, further supporting the notion that vaccination with native peptide was very 
successful at inducing robust cytolytic activation of most T-cells. 
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DISCUSSION 
Peptide-based cancer vaccines are often performed with altered “analog” peptide antigens that 
have been optimized for enhanced MHC class I binding, resulting in superior T-cell 
immunogenicity 26. This is illustrated in studies where the immunodominant HLA-A*0201-
restricted peptide of the melanoma antigen Melan-AMART-126-35 (EAAGIGILTV) was modified 
by an Ala to Leu substitution at position 27 (A27L; ELAGIGILTV) 18, 27-29. This model 
provides ideal opportunities to assess possible effects of a small antigenic difference on the in 
vivo quality (e.g. effector functions, stage of differentiation, and clonotype selection) of the 
generated T-cell responses. Compared with vaccination with the analog Melan-A peptide, we 
previously reported that native peptide induced T-cells with increased activation and effector 
function 19. These observed differences could not be explained by structurally distinct TCRs, 
since vaccination with native and analog peptide triggered largely overlapping TCR 
repertoires with structurally conserved features of TCRαβ chains 30. Here, we demonstrate 
that the superior tumor activity by native peptide induced T-cells is because effector functions 
developed properly in nearly all dominant and low/non dominant tumor-specific T-cell 
clonotypes. In contrast, many T-cells remained poorly functional after vaccination with 
analog peptide, despite sharing similar clonotype-dependent differentiation. Thus, a single 
amino acid substitution within a peptide vaccine can have significant consequences on the 
quality of the T-cell response.  
The present study allowed for the first time to determine effector function-associated gene 
expression by individual T-cells ex vivo, including low/non-dominant clonotypes (Fig. 7). 
Indeed, single-cell analysis provides reliable quantification of individual cells expressing a 
particular gene, as confirmed by protein expression analyses. Moreover, our strategy is highly 
sensitive to identify tumor-reactive T-cell clonotypes and to assess their frequencies (Fig. 7), 
and is in excellent agreement with the data obtained by the in vitro T-cell cloning approach 
(Fig. 1; 16) (Gupta, Iancu et al., manuscript in preparation). An analogous approach has been 
previously and successfully applied to study cell heterogeneity during in vivo CD8 
differentiation 23, 31. Here we found that anti-tumor T-cell effector function is primarily 
determined by the type of peptide used for vaccination (native versus analog) and is not 
inherent of a given T-cell clonotype or of its prevalence (dominant versus non-dominant). 
Moreover, similar distributions in effector gene expression signatures were found between T-
cell clonotypes issued from the same subset of differentiation (Fig. 7). Comparable 
observations were made for EBV- and CMV-specific T-cells, indicating that the functional 
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profile of individual T-cells is also influenced by the differentiation status. As a consequence, 
most if not all clonotypes from a given subset of differentiation and participating in a tumor 
(self) or viral (non-self) T-cell response may be equally competent. Selection of a T-cell 
repertoire composed of low/(non)-dominant and dominant clonotypes could serve to promote 
clonotypic diversity, while maintaining functional competence. These results are consistent 
with the report by Messaoudi and colleagues 32 that a diverse TCR repertoire but not a 
restricted one can mobilize protective antigen-specific T-cells of high avidity and efficient 
target cell killing.  
Our data also show that a synthetic vaccine (i.e. decapeptide, CpG and IFA 18) was able to 
trigger a similar composition of T-cell clonotypes as in viral infections, 7, 17, and particularly 
in EBV-specific T-cell responses 16. Responding T-cells were composed of clonotypes of 
varying frequencies (dominant, subdominant and non-dominant), yet the proportion of each 
frequency-based clonotypes was dependent on the differentiation stage (Fig. 7). Late-
differentiated EM28neg (“effector-like”) consisted primarily of patient specific dominant (high 
frequency) and subdominant (low frequency) clonotypes with long-term persistence. In 
contrast, the early-differentiated EM28pos subset (that includes effector-memory cells) 
contained mostly non-dominant clonotypes with only a small fraction (25%) of co-dominant 
T-cell clonotypes. Thus, clonotypic diversity was mostly found within the effector-memory 
subset, contrasting with advanced differentiation stages that contained some clonotypes that 
were enriched, while others were not. This process is likely to be clonotype-dependent, 
consistent with studies on T-cells specific for persistent viruses 7, 17, and highlighting the 
importance of the structural composition of the TCR repertoire for T-cell differentiation. 
Moreover, many tumor-specific clonotypes identified in the late-differentiated effector-like 
subset were also found within the pool of less-differentiated “effector-memory” cells, albeit at 
much lower frequencies. Co-existence of identical clonotypes as both effector-memory and 
effector T-cells has also been described for human T-cells specific for influenza matrix 
protein peptide 33 and HIV epitopes 17. Together, these observations are in line with recent 
findings by Gerlach and coworkers 34, showing that individual naive T-cells have multiple 
fates and can differentiate into both memory and effector T-cell subsets. 
What are the processes involved during recruitment and subsequent maintenance of dominant 
and low/(non)-dominant clonotypes along a T-cell response? The strength of the TCR-ligand 
interactions, also defined as TCR binding affinity/avidity, has been proposed to represent one 
of the driving forces underlying clonal selection and expansion. Consistent with this notion, 
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very weak interactions were sufficient for T-cell activation and induction of functional 
memory cells, while stronger TCR ligation allowed the preferential expansion of T-cells with 
increased affinity/avidity 35. Price and colleagues have shown that dominant T-cell clonotypes 
specific for persistent herpes viruses exhibited increased pMHC binding avidity, compared to 
subdominant clonotypes, mostly characterized by a greater dependency on the MHCI-CD8 
interactions 7. These findings provide evidence that the binding avidity for the antigen shapes 
clonal dominance, while the CD8 co-receptor may compensate for those differences in TCR 
affinity/avidity by keeping a diverse and heterogeneous T-cell clonotype repertoire within a 
physiological range of functional competence 36. Whether similar physical parameters may 
also apply for vaccination-induced tumor-specific T-cell responses remains unclear. Future 
investigations should include binding analysis to pMHC, as well as assessing expression 
levels of accessory and/or costimulatory molecules by low/(non)-dominant and dominant 
clonotypes.  
A remarkably finding was that vaccination with native but not analog peptide was more rapid 
and more efficient at inducing the expression of multiple effector molecules in nearly all 
Melan-A-specific T-cell clonotypes. This correlated with efficient target cell killing. 
Consequently, both native-peptide vaccination-induced T-cell subsets (EM28pos and 
EM28neg), closely resembled each other, and to the highly differentiated CMV-specific T-cells 
(Fig. 7). These data refine our current view of the process of T-cell differentiation, as they 
indicate that progressive up-regulation of cytolytic activity does not necessarily require the 
stepwise loss of costimulatory (CD27, CD28) and cytokine receptor (IL-7Rα) expression. 
Previous reports have described a hierarchical order of T-cell differentiation stages, from 
naïve to CM, EM28pos, EM28neg and EMRA cells 21-23, 37, 38. Specifically, Monteiro and 
colleagues showed that cellular differentiation (loss of CCR7/CD27/CD28 co-expression) led 
to a progressive up-regulation of multiple “killer” mediators by the same cell 23. This report 
together with our own observations 22 has provided a tight correlation between particular cell 
surface markers (e.g. CCR7+/-, CD28+/-, and CD27+/-) and T-cell functional properties. While 
these studies were performed on circulating “bulk” CD8 T-cells, an alternative picture became 
apparent when assessing virus antigen-specific T-cells. Indeed, despite showing distinct 
expression patterns along with cell differentiation, CMV-specific cells also expressed globally 
higher levels of CD94, CD57, IFN-γ, perforin and granzyme B than EBV-specific cells (Fig. 
7; 16). In line with this observation, we show here that vaccination with the native self/tumor 
Melan-A peptide was able to further enhance the expression of effector mediators among 
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tumor-specific T-cells despite their co-expression of early-differentiated surface markers, 
CD27, CD28 and IL-7Rα.  
What are the mechanisms causing accelerated differentiation and enhanced expression of 
effector mediators observed following vaccination with the native peptide? Possibly, 
vaccination with native peptide may recruit T-cells of superior TCR affinity/avidity, selected 
to overcome the lower peptide binding to MHC (the analog peptide binds 10 times more 
stably to HLA-A2 than the native peptide 27). Alternatively, high avidity T-cells generated by 
analog peptide vaccination may be more susceptible to apoptosis. Furthermore, T-cell priming 
and activation may depend on the relative signals during interaction with APCs, involving 
costimulation and cytokines. The differences observed in effector functions between native or 
analog peptide vaccination-induced T-cells may also be independent of the primary TCR 
structure, and rather involve differential TCR and coreceptor supramolecular organization 39, 
40 as well as basal T-cell activation (e.g. phosphorylation) status 41. 
Our current study shows that clonotype-dependent and clonotype-independent processes, 
respectively, shape the structural and functional composition of tumor-specific vaccination-
induced T-cells, similarly to EBV- and CMV-specific T-cell responses. High-resolution 
characterization of individual T-cells at the clonotype level as shown here, provide the basis 
to identify the biological benchmarks associated with protective T-cell immunity, contributing 
to the rationale development of vaccines.  
  
 
   
 15 
FIGURE LEGENDS 
Figure 1. TCR BV repertoire diversity analysis and quantification of Melan-A-specific T-cell 
clonotypes. A, Fifteen patients vaccinated with the analog (ELA; n = 10) or the native (EAA; 
n = 5) peptide were followed over time (# of monthly vaccinations, duration of vaccination, 
see Supporting Information) and characterized for their specific T-cell immune responses (e.g. 
persistence of T-cell clonotypes over time). Mo, months. B, cDNA pools (50 cells) generated 
from ex vivo EM28pos and EM28neg tumor-specific T-cells sorted from peripheral blood from 
patients vaccinated with the native or analog peptide were amplified by PCR using 22 BV-
specific primers, and subjected to electrophoresis (TCR BV spectratyping). BV repertoire 
diversity is expressed as the total number of amplified BV-CDR3-BC products of different 
lengths within each positive BV families. The analysis comprised blood samples collected at 
1 to 3 separated time-points per patient following vaccination. * 0.01 < P < 0.05, *** P < 
0.005 (two-tailed unpaired t test). C, Frequencies of Melan-A-specific T-cell clonotypes 
determined by CDR3 size lengths, sequencing and clonotypic PCR. This part of the study was 
performed on in vitro generated T-cell clones from patients vaccinated either with analog 
peptide (LAU 618, n = 513; LAU 672, n = 161) or native peptide (LAU 972, n = 139; LAU 
1013, n = 134). Time-points after vaccination were 14 mo (LAU 618), 16 mo (LAU 672), 8 
mo (LAU 972) and 8 mo (LAU 1013), respectively. Each clonotype (frequency ≥ 1%) is 
indicated and each TCR BV family is color-coded. Non-dominant clonotypes are designed as 
“BV other” and are comprised of clonotypes of unique TCR BV/CDR3 sizes and/or BV-
CDR3-BC sequences as determined by capillary electrophoresis and sequencing. 
 
Figure 2. Comparison of early and late time-points of TCR BV repertoire diversity and 
clonotype frequency of circulating Melan-A-specific CD8 T-cell subsets analyzed ex vivo. A 
and B, BV spectratyping was performed on cDNA obtained from individually sorted 5-cell 
samples (n = 8 to 20) of specific EM28pos (upper panel) and EM28neg (lower panel) T-cells 
isolated from patients at the indicated time-points after vaccination with the analog peptide 
(A) or the native peptide (B). Dominant TCR clonotypes (defined as identical BV-CDR3-BC 
sequence found at least twice) and non-dominant single TCR clonotypes (defined by their 
unique TCR BV/CDR3 size length and/or BV-CDR3-BC sequence). Data are represented as 
the total number (y-axis) of dominant (filled area) and single (grey area) clonotypes of 
defined TCR BV family (x-axis) versus defined CDR3 size length (z-axis). Representative 
examples are depicted. C, Complete set of data (9 and 5 patients vaccinated with the analog or 
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native peptide, respectively) representing the proportion of single (left panel) and dominant 
(right panel) clonotypes identified within the EM28neg subset of the indicated patient cohort 
and time-point after vaccination. Of note, patient LAU 444 (vaccinated with analog peptide) 
was not included in this analysis, since we identified a single dominant T-cell clonotype of 
high frequency prevailing already before immunotherapy, which was apparently naturally 
primed and rapidly and predominantly boosted upon vaccination 14. Early time-point, 1 to 3 
months; late time-point, > 3 to 21 months. Dominant clonotypes were classified according to 
their relative frequencies among tumor-specific EM28neg subsets as > 25%, high frequency 
(empty symbols) and 1-25%, intermediate frequency (filled symbols). Due to the limited 
amount of sorted EM28neg T-cells from patients vaccinated with the analog peptide at early 
time-points compared to late time-points, reduced numbers of samples were analyzed. P-
values were calculated with two-tailed unpaired t test. 
 
Figure 3. Gene expression profiling of single T-cells sorted ex vivo upon gating on tumor- 
and virus-specific CD8 T-cell subsets. A, Single-cells were isolated from EM28pos and 
EM28neg (patients vaccinated either with analog/ELA or native/EAA peptide), and from 
EM28pos and EMRA (EBV- and CMV-specific T-cells from the healthy individual BCL8) T-
cell subsets, subjected to global cDNA amplification, and analyzed by specific PCR 
amplification of CCR7, CD27, IL-7Rα, CD94, IFN-γ, perforin and granzyme B known to be 
differentially expressed at distinct stages of cell differentiation 14, 22. GAPDH gene expression 
was analyzed as quality control. Positive PCRs are depicted in red and negative ones in blue. 
Compiled data are shown per subset and per patient/healthy individual, where each line 
represents a single T-cell. Analysis was performed at the same time-points after vaccination 
as those depicted in Fig. 1C. B, Complete sets of data of the proportion of each expressed 
gene in early- (EM28pos) or late- (EM28neg, EMRA) differentiated subsets from patients 
vaccinated with analog peptide (LAU 618, ; LAU 672, ) and native peptide (LAU 1013, 
; LAU 972, ), and from healthy donors BCL8 (EBV, ; CMV, ) and BCL6 (CMV, ). 
C, A hierarchical clustering (left panel) of the complete data sets (n = 529 single-cell samples) 
depicted in (A), based on Euclidean distance between samples with the UPGMA clustering 
method. The cluster dendrogram identifies 5 distinct clusters (minimum similarity set to 
0.375). The repartition of these clusters within the single-cell samples of each EM28pos and 
EM28neg T-cell subset (specific for ELA, EAA, EBV or CMV) was then determined by Heat-
map analysis (right panel). Of note, single cell samples from EM28pos antigen-specific subsets 
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were mostly found within clusters I-III (IFN-γlow, perflow and granBlow), whereas those from 
EM28neg subsets were classified in clusters II, IV and V (IFN-γhigh, perfhigh and granBhigh). 
 
Figure 4. Ex vivo expression of effector mediators within tumor- and virus-specific CD8 T-
cell subsets. A, The proportion of CD57, perforin and granzyme B protein expression among 
antigen-specific EM28pos and EM28neg subsets was determined by multi-parameter flow 
cytometry. The dotted line was set according to the gating obtained on bulk CD8pos naive T-
cells known to be CD57negperforinneggranzymeBneg. Representative examples are shown. B, A 
complete set of data was obtained from melanoma patients following analog (ELA, n = 10) or 
native (EAA, n= 5) peptide vaccination, and from healthy individuals with EBV (n= 5) and/or 
CMV (n = 5) specific T-cell responses. * 0.01 < P < 0.05, ** 0.005 < P <0.01, *** P < 0.005 
(two-tailed unpaired t test). 
 
Figure 5. Characterization of gene expression profiles combined with clonotyping. Poly-
functional gene expression was determined for representative dominant (A) and non-dominant 
(B) tumor- and virus-specific T-cell clonotypes, upon ex vivo single-cell sorting (n = 529) of 
EM28pos and EM28neg/EMRA T-cells. Dominant clonotypes (A) are defined according to their 
relative frequencies within a specific subset as high (> 10 %) or intermediate (1-9 %) 
frequency, and non-dominant TCRs (B) as frequencies < 1%. The pie charts illustrate the co-
expression profiles of CD94, IFN-γ, perforin and granzyme B within the single-cell samples. 
 
Figure 6. Tumor cell killing and efficiency of antigen recognition. Tumor-specific T-cell 
clones were generated in vitro by limiting-dilution from blood samples corresponding to the 
same time-points after vaccination as those depicted in Fig. 2. A, Tumor reactivity for the 
melanoma cell lines Me 290 (A2+/Melan-A+) and NA8 (A2+/Melan-A-) in absence or 
presence of Melan-A analog peptide (1 µM), at an effector:target ratio of 30:1. Each line 
represents the result of an individual clone derived from EM28pos or EM28neg subsets from 
patients vaccinated either with analog (ELA; n = 153) or native peptide (EAA; n = 80). T-
cells were grouped for low, intermediated, and high target cell lysis (i.e. < 20% (red), 20-60% 
(yellow), and >60% (green)). B, Complete data representing specific lysis of the Melan-A+ 
Me 290 tumor cell line in the absence of exogenous Melan-A peptide (10:1; effector:target 
ratio) by dominant and non-dominant T-cell clones derived from EM28pos and EM28neg 
   
 18 
subsets of patients vaccinated with analog (grey whiskers) or native peptide (empty whiskers). 
C, The relative TCR avidity was compared using T2 target cells (A2+/TAP-/-) pulsed with 
graded concentrations of analog/ELA Melan-A26-35 peptide. EM28pos and EM28neg T-cells 
were defined as dominant and non-dominant BV clonotypes. Complete data representing 
maximal lysis (upper panel) and EC50 (e.g. peptide concentration required to achieve 50% of 
maximal lysis; lower panel). We used the same clones as in A and B. Clones with 
undetectable lytic activity (EC50 > 10-6 M and/or maximal lysis < 20%) are symbolized as 
single dots above the y-axis and were not included in the statistical evaluations. * 0.01 < P < 
0.001, ** 0.001 < P <0.0001, *** P < 0.0001 (two-tailed unpaired t test). 
 
Figure 7. Clonotypic and functional composition of vaccination-induced tumor-specific and 
virus-specific T-cell repertoire revealed by ex vivo single cell analysis. Each clonotype is 
represented by its frequency (inner circle) and its poly-functional effector gene expression 
profile (outer circle). Increased frequency and poly-functional gene expression (co-expression 
of CD94, IFN-γ, perforin and granzyme B) are depicted as progressive color gradients. Data 
from four patients vaccinated with the analog (LAU 618 and LAU 672) and native (LAU 
1013 and LAU 972) Melan-A peptide, and from two healthy individuals (BCL6 and BCL8; 
EBV and CMV-specific T-cell responses) are shown.  
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METHODS 
Patients and vaccination, and healthy blood donors  
Fifteen HLA-A*0201-positive patients with stage III/IV metastatic melanoma were included 
in a phase I prospective trial of the Ludwig Institute for Cancer Research and the 
Multidisciplinary Oncology Center, approved by institutional review boards and regulatory 
agencies 18, 19. Patients received monthly low-dose vaccinations injected subcutaneously with 
100 µg of either the Melan-AMART-126-35 unmodified native peptide (EAAGIGILTV) or the 
Melan-AMART-126-35 analog A27L peptide (ELAGIGILTV), mixed with 0.5 mg CPG 7909 / 
PF-3512676 (Pfizer and Coley Pharmaceutical Group) and emulsified in Incomplete Freund’s 
Adjuvant (IFA) (Montanide ISA-51; Seppic)18. Leukapheresis from two healthy donors 
(BCL6 and BCL8) with positive EBV- and CMV-specific CD8 T-cell responses were 
collected upon informed consent as recently described 16.  
 
Cell preparation and flow cytometry 
Ficoll-Paque centrifuged peripheral blood mononuclear cells (PBMCs) were cryopreserved in 
RPMI 1640, 40% FCS and 10% DMSO. Synthesis of phycoerythrin (PE)-labeled HLA-
A*0201/peptide multimers with A27L Melan-AMART-126-35 (ELAGIGILTV), EBV BMLF1280-
288 (GLCTLVAML), and CMV pp65495-503 (NLVPMVATV) was prepared as described 
previously 42. Before staining, CD8pos T-cells were positively enriched using a MiniMACS 
device (Miltenyi Biotech, Bergish Gladbach, Germany) resulting in > 90% CD3posCD8pos 
cells. Cells were stained in PBS, 0.2% BSA, 50 µM EDTA with multimers (1 µg/ml, 60 min, 
4°C) and then with appropriate mAbs (20 min, 4°C), and sorted into defined sub-populations 
on a FACSVantage SE or a FACSAria (BD PharMingen, San Diego, CA) or immediately 
analyzed on a LSR IITM flow cytometer (BD Biosciences) as described in the Supplemental 
Information. For dead cell exclusion, cells were stained with Live/Dead Fixable Dead Cell 
violet stain (Molecular Probes / Invitrogen). Intracellular content of granzyme B and perforin 
was measured in freshly isolated CD8pos T lymphocytes without previous stimulation as 
described elsewhere 14. Data were analyzed using CellQuest (BD Biosciences) or FlowJo 
(TreeStar) software. 
 
Generation of T-cell clones 
HLA-A2/multimerpos CD8pos T-cell subsets (EM28pos, EM28neg, and EMRA) were sorted by 
flow cytometry 14, 16, cloned by limiting dilution, and expanded in RPMI 1640 medium 
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supplemented with 8% human serum, 150 U/ml recombinant human IL-2 (rhIL-2; a gift from 
GlaxoSmithKline), 1 µg/ml phytohemagglutinin (PHA; Sodiag, Losone, Switzerland) and 1 × 
106/ml irradiated allogeneic PBMC (3000 rad) as feeder cells. T-cell clones were expanded by 
periodic (every 15 days) restimulation with PHA, irradiated feeder cells, and rhIL-2. 
 
cDNA preparation and amplification 
cDNA preparation, cDNA amplification and PCR were performed as described in 
Supplemental Information and elsewhere 24. In brief, single-cell or 5-cell aliquots were sorted 
with a FACSVantage SE or FACSAria machine into 96-V bottom plates containing 
lysis/reverse transcription mix for direct cDNA synthesis. cDNA from single-cell or 5-cell 
aliquots was precipitated, and global cDNA amplification by RT-PCR was performed 
following the addition of an homopolymer d(A) sequence to the 3’-OH end. 105 cells from T-
cell clones were processed through direct lysis and cDNA synthesis without undergoing the 
global cDNA amplification procedure. 
 
Gene expression and TCR BV clonotype repertoire analysis 
Single-cell samples were subjected to specific PCR reactions using the primers to detect 
GAPDH, CD3, CCR7, CD27, CD94, IFN-γ, perforin and granzyme B mRNA transcripts that 
are described in the Supplemental Information. TCR BV CDR3 spectratyping, sequencing and 
clonotyping were performed as detailed in the Supplemental Information, and recently 30. All 
ex vivo single-cell, 5-cell or in vitro T-cell clone cDNA samples, isolated from defined tumor-
specific T-cell subsets (EM28pos or EM28neg) from patients vaccinated either with native or 
analog peptide were processed with the same rigorous approach to allow direct comparison 
between individuals. TCR Vβ usage and sequences were described according to the Arden 
nomenclature 43. Term of “dominant clonotype” refers to a nucleotide sequence found at least 
twice in a given patient and time-point (> 1% of frequency) 30. 
 
Chromium release and tumor recognition assays 
Lytic activity and antigen recognition was assessed functionally in 4-h 51Cr-release assays 
using T2 target cells (HLA-A*0201+/Melan-A-) pulsed with serial dilutions of the native 
Melan-AMART-126-35 peptide (EAAGIGILTV) or of the analog Melan-AMART-126-35 A27L 
(ELAGIGILTV) 44. The percentage of specific lysis was calculated as 100 × (experimental − 
spontaneous release)/(total − spontaneous release). Similarly, the specific antigen recognition 
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lytic activity of the Melan-AMART-1-specific T-cell clonotypes was assessed against the 
melanoma cell lines NA8 (HLA-A2+/Melan-A-) and Me 290 (HLA-A2+/Melan-A+) in the 
presence or absence of the indicated peptide at the indicated concentration. 
 
Statistical and hierarchical clustering analyses 
The results were analyzed by unpaired two-sample t test and log sigmoid curve fitting using 
GraphPad Prism version 5.03 (GraphPad Software, San Diego, CA). Hierarchical 
agglomerative clustering and dendrogram display of gene expression data were performed 
with HCE (Hierarchical Clustering Explorer) version 3.5 (http://www.cs.umd.edu/hcil/hce/). 
All PCR results were encoded into a data matrix in which the assigned value was +1 for a 
positive PCR product and 0 for a negative PCR product. The data were examined without 
normalization/transformation using Euclidean distance with the Unweighted Pair Group Mean 
Arithmetic (UPGMA) clustering method. Control genes (GAPDH and CCR7) were not 
included during clustering analysis. 
   
 22 
REFERENCES 
1. Blattman, J.N. et al. Estimating the precursor frequency of naive antigen-specific CD8 T cells. 
J Exp Med 195, 657-664 (2002). 
2. Nikolich-Zugich, J., Slifka, M.K. & Messaoudi, I. The many important facets of T-cell 
repertoire diversity. Nat Rev Immunol 4, 123-132 (2004). 
3. Gourley, T.S., Wherry, E.J., Masopust, D. & Ahmed, R. Generation and maintenance of 
immunological memory. Semin Immunol 16, 323-333 (2004). 
4. Speiser, D.E., Kyburz, D., Stubi, U., Hengartner, H. & Zinkernagel, R.M. Discrepancy 
between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T 
cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to 
peptide-coated target cells but not for in vivo protection. J Immunol 149, 972-980 (1992). 
5. Almeida, J.R. et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their 
avidity, polyfunctionality, and clonal turnover. J Exp Med 204, 2473-2485 (2007). 
6. Lichterfeld, M. et al. Selective depletion of high-avidity human immunodeficiency virus type 
1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J Virol 81, 4199-4214 (2007). 
7. Price, D.A. et al. Avidity for antigen shapes clonal dominance in CD8+ T cell populations 
specific for persistent DNA viruses. J Exp Med 202, 1349-1361 (2005). 
8. Appay, V., Douek, D.C. & Price, D.A. CD8+ T cell efficacy in vaccination and disease. Nat 
Med 14, 623-628 (2008). 
9. Seder, R.A., Darrah, P.A. & Roederer, M. T-cell quality in memory and protection: 
implications for vaccine design. Nat Rev Immunol 8, 247-258 (2008). 
10. Almeida, J.R. et al. Antigen sensitivity is a major determinant of CD8+ T-cell 
polyfunctionality and HIV-suppressive activity. Blood 113, 6351-6360 (2009). 
11. Price, D.A. et al. Public clonotype usage identifies protective Gag-specific CD8+ T cell 
responses in SIV infection. J Exp Med 206, 923-936 (2009). 
12. Romero, P. et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as 
targets for tumor reactive CTL in human melanoma. Immunol Rev 188, 81-96 (2002). 
13. Boon, T., Coulie, P.G., Van den Eynde, B.J. & van der Bruggen, P. Human T cell responses 
against melanoma. Annu Rev Immunol 24, 175-208 (2006). 
14. Speiser, D.E. et al. A novel approach to characterize clonality and differentiation of human 
melanoma-specific T cell responses: spontaneous priming and efficient boosting by 
vaccination. J Immunol 177, 1338-1348 (2006). 
15. Derre, L. et al. In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not 
Limited by Replicative Senescence or Functional Alteration. J Immunol 179, 2368-2379 
(2007). 
16. Iancu, E.M. et al. Clonotype selection and composition of human CD8 T cells specific for 
persistent herpes viruses varies with differentiation but is stable over time. J Immunol 183, 
319-331 (2009). 
17. Meyer-Olson, D. et al. Clonal expansion and TCR-independent differentiation shape the HIV-
specific CD8+ effector-memory T-cell repertoire in vivo. Blood 116, 396-405. 
18. Speiser, D.E. et al. Rapid and strong human CD8+ T cell responses to vaccination with 
peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115, 739-746 (2005). 
19. Speiser, D.E. et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor 
reactivity than altered antigen. Proc Natl Acad Sci U S A 105, 3849-3854 (2008). 
20. Speiser, D.E. et al. In vivo activation of melanoma-specific CD8(+) T cells by endogenous 
tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 32, 
731-741 (2002). 
21. Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T 
lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-712 
(1999). 
22. Romero, P. et al. Four functionally distinct populations of human effector-memory CD8+ T 
lymphocytes. J Immunol 178, 4112-4119 (2007). 
   
 23 
23. Monteiro, M., Evaristo, C., Legrand, A., Nicoletti, A. & Rocha, B. Cartography of gene 
expression in CD8 single cells: novel CCR7- subsets suggest differentiation independent of 
CD45RA expression. Blood 109, 2863-2870 (2007). 
24. Rufer, N., Reichenbach, P. & Romero, P. Methods for the ex vivo characterization of human 
CD8+ T subsets based on gene expression and replicative history analysis. Methods Mol Med 
109, 265-284 (2005). 
25. Barbey, C. et al. IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human 
CD28+ cytolytic T cells. J Immunol 178, 3566-3574 (2007). 
26. Rosenberg, S.A., Yang, J.C. & Restifo, N.P. Cancer immunotherapy: moving beyond current 
vaccines. Nat Med 10, 909-915 (2004). 
27. Valmori, D. et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected 
Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160, 1750-1758 (1998). 
28. Rivoltini, L. et al. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-
melanoma CD8+ T cells with enhanced functional characteristics: implication for more 
effective immunotherapy. Cancer Res 59, 301-306 (1999). 
29. Ayyoub, M. et al. Activation of human melanoma reactive CD8+ T cells by vaccination with 
an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T 
cells-1. Clin Cancer Res 9, 669-677 (2003). 
30. Wieckowski, S. et al. Fine structural variations of alphabetaTCRs selected by vaccination with 
natural versus altered self-antigen in melanoma patients. J Immunol 183, 5397-5406 (2009). 
31. Peixoto, A. et al. CD8 single-cell gene coexpression reveals three different effector types 
present at distinct phases of the immune response. J Exp Med 204, 1193-1205 (2007). 
32. Messaoudi, I., Guevara Patino, J.A., Dyall, R., LeMaoult, J. & Nikolich-Zugich, J. Direct link 
between mhc polymorphism, T cell avidity, and diversity in immune defense. Science 298, 
1797-1800 (2002). 
33. Touvrey, C. et al. Dominant human CD8 T cell clonotypes persist simultaneously as memory 
and effector cells in memory phase. J Immunol 182, 6718-6726 (2009). 
34. Gerlach, C. et al. One naive T cell, multiple fates in CD8+ T cell differentiation. J Exp Med 
207, 1235-1246. 
35. Zehn, D., Lee, S.Y. & Bevan, M.J. Complete but curtailed T-cell response to very low-affinity 
antigen. Nature 458, 211-214 (2009). 
36. Couedel, C. et al. Selection and long-term persistence of reactive CTL clones during an EBV 
chronic response are determined by avidity, CD8 variable contribution compensating for 
differences in TCR affinities. J Immunol 162, 6351-6358 (1999). 
37. Appay, V. et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent 
virus infections. Nat Med 8, 379-385 (2002). 
38. Rufer, N. et al. Ex vivo characterization of human CD8+ T subsets with distinct replicative 
history and partial effector functions. Blood 102, 1779-1787 (2003). 
39. Fahmy, T.M., Bieler, J.G., Edidin, M. & Schneck, J.P. Increased TCR avidity after T cell 
activation: a mechanism for sensing low-density antigen. Immunity 14, 135-143 (2001). 
40. Cawthon, A.G. & Alexander-Miller, M.A. Optimal colocalization of TCR and CD8 as a novel 
mechanism for the control of functional avidity. J Immunol 169, 3492-3498 (2002). 
41. Kersh, E.N. et al. TCR signal transduction in antigen-specific memory CD8 T cells. J 
Immunol 170, 5455-5463 (2003). 
42. Pittet, M.J. et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a 
large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp 
Med 190, 705-715 (1999). 
43. Arden, B., Clark, S.P., Kabelitz, D. & Mak, T.W. Human T-cell receptor variable gene 
segment families. Immunogenetics 42, 455-500 (1995). 
44. Romero, P. et al. CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro 
immunogenicity of natural and analogue sequences. Clin Cancer Res 7, 766s-772s (2001). 
 
 
   
 24 
Figure 1 
 
 
   
 25 
Figure 2 
 
 
   
 26 
Figure 3 
 
   
 27 
Figure 4 
 
   
 28 
Figure 5 
 
   
 29 
Figure 6 
 
   
 30 
Figure 7 
 
   
 31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUPPORTING INFORMATION 
 
   
 32 
Supplemental Table 1. Clinical characteristics of patients 
Patient Gender 
Age at 
diagnosis 
(years) 
Disease stage at 
diagnosis  Type of vaccine
1 
# of 
vacci-
nations 
Duration2 
(mo) 
Clinical 
outcome 
LAU 205 M 24 pT2aN1M0 ELA+IFA+CpG 20 22.4 † 
LAU 321 M 60 pT3aN0M0,IIa ELA+IFA+CpG 8 7.5   
LAU 371 F 30 pT3aN1M0,III ELA+IFA+CpG 6 6.1 † 
LAU 444 F 28 pT3aN0M0 ELA+IFA+CpG 20 21.9 † 
LAU 618 F 70 pT4N0M0 ELA+IFA+CpG 12 11.9   
LAU 672 M 35 pT1N0M0 ELA+IFA+CpG 4 2.8 † 
LAU 818 M 55 pT3bN0M0,IIb ELA+IFA+CpG 18 20.5   
LAU 936 F 52 pT3aN0M0,IIa ELA+IFA+CpG 7 7.0 † 
LAU 944 F 20 pT1aN0M0 ELA+IFA+CpG 16 16.3   
LAU 1164 M 52 pTxNxM1a ELA+IFA+CpG 14 36.0   
LAU 972 F 60 pT2bN1M0 EAA+IFA+CpG 20 21.5   
LAU 975 M 52 pT4N1bM0 EAA+IFA+CpG 4 2.9 † 
LAU 1013 M 56 pT3bN3M0 EAA+IFA+CpG 8 8.4 † 
LAU 1015 M 75 pT2aN0M1a,IV EAA+IFA+CpG 20 22.4 † 
LAU 1106 M 36 pT2aN1M0,IIIa EAA+IFA+CpG 27 44.8   
1 ELA refers to the analog peptide and EAA to the native unmodified peptide 
2 Time (months) during which the patient received monthly vaccinations 
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SUPPLEMENTAL FIGURE LEGENDS 
 
Supplemental Figure 1. Ex vivo analysis of circulating Melan-AMART-1 26-35 specific CD8 
T-cells over time in melanoma patients vaccinated with either the analog A27L-modified (A; 
n = 10) or the unmodified native (B; n = 5) peptide, combined with CpG and IFA. A and B, 
Percentages of CD28pos (empty bars) and CD28neg (filled bars) Melan-AMART-1-specific T-
cells in CD8pos T-cells from peripheral blood was measured by flow cytometry at the indicated 
time-points before (defined as time 0) and after vaccination, using CD8- and CD28-specific 
Abs and HLA-A2/Melan-AMART-1 multimers. For patients LAU 371, LAU 936, and LAU 
1013, the proportion of multimerpos T cells was below ≤ 0.02% before the start of peptide 
vaccination. Vaccinations are indicated by filled circles. 
 
Supplemental Figure 2. TCR BV diversity analysis and quantification of Melan-A-specific 
T-cell clonotypes. A, cDNA pools (50 cells) generated from ex vivo EM28pos and EM28neg 
tumor-reactive T-cells sorted from blood of patients vaccinated with analog (LAU 618 and 
LAU 672) or native (LAU 972 and LAU 975) peptide were amplified by PCR using 22 BV-
specific primers and subjected to electrophoresis. Each BV subfamily (x-axis) was analyzed 
for the presence of amplified BV-CDR3-BC products of defined CDR3 size (y-axis), and 
displayed by black squares on a grid. The figures inserted in each grid indicate the # of TCR 
BV subfamily usage versus the # of all amplified BV-CDR3-BC products. B, Clonotypic PCR 
was performed on in vitro generated specific T-cell clones from patients vaccinated either 
with analog (LAU 936, n = 91; LAU 1164, n = 120) or native peptide (LAU 1015, n = 204; 
LAU 1106, n = 130). Time-points after start of vaccination were 7 mo (LAU 936), 1 mo 
(LAU 1164), 13 mo (LAU 1015) and 8 mo (LAU 1106), respectively. Each clonotype with a 
frequency ≥ 1% is indicated. Non-dominant clonotypes are designed as “BV other” and are 
comprised of clonotypes of unique TCR BV/CDR3 sizes and/or BV-CDR3-BC sequences as 
determined by capillary electrophoresis and sequencing. C, Repartition of dominant and non-
dominant T-cell clonotypes within EM28pos and EM28neg T-cell subsets and within antigenic 
specificities (analog/ELA or native/EAA tumor antigens, EBV or CMV epitopes). Dominant 
clonotypes are defined as high (≥ 10 %, in blue) or intermediate (1-9 %, green) frequency. 
The proportion of non-dominant clonotypes (< 1%) is depicted in grey. Mo, months. 
 
Supplemental Figure 3. Analysis of T-cell clonotype diversity and frequency in circulating 
Melan-A-specific T-cell subsets over time. TCR BV spectratyping was performed on cDNA 
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obtained from individually sorted 5-cell samples of specific EM28pos and EM28neg CD8 T 
cells from patients after vaccination with analog (n = 9) or native peptide (n = 5). A, Complete 
data representing the proportions of single non dominant (left panel) and dominant (right 
panel) clonotypes identified in the EM28pos subset of the indicated patient cohort and time-
point after vaccination. Early time-point, 1 to 3 months; late time-point, > 3 months. 
Dominant TCR clonotypes are defined as identical BV-CDR3-BC sequences found at least 
twice and non-dominant single TCR clonotypes are defined by their unique TCR BV/CDR3 
size length and/or BV-CDR3-BC sequence. Dominant clonotypes were further classified 
according to their relative frequencies among tumor-specific EM28pos subsets as high 
frequency (i.e. > 25%; empty symbols) and intermediate frequency (i.e. 1-25%, filled 
symbols). P-values were calculated with the two-tailed unpaired t test. B, Collection of 
dominant T-cell clonotypes shared between EM28pos and EM28neg subsets of patients 
vaccinated with analog (ELA) or native (EAA) peptide. For each clonotype, we indicate the 
type of peptide vaccination, the patient code, the time-point tested after vaccination, and its 
frequency within EM28pos and EM28neg subsets. 
 
Supplemental Figure 4. Ex vivo gene expression analysis of effector mediators in Melan-A-
specific CD8 T-cell subsets at the single-cell level. A, Examples of gene expression profiles in 
two patients vaccinated with the analog peptide (LAU 672) or the native peptide (LAU 972). 
Primers designed for GAPDH, CCR7, CD27, IL-7Rα, CD94, IFN-γ, perforin and granzyme B 
mRNA transcripts are depicted. Data from 15 independent single-cell aliquots are shown. B, 
The pie charts depict co-expression profiles of CD94, IFN-γ, perforin and granzyme B within 
the single-cell samples of tumor- and virus-specific EM28pos and EM28neg/EMRA T-cell 
subsets.  
 
Supplemental Figure 5. Ex vivo analysis of expression of effector proteins in Melan-A-
specific CD8 T-cell subsets by multi-parameter flow cytometry. A, The proportion of CD27, 
IL-7Rα and PD1 protein expression was determined within EM28pos and EM28neg T-cell 
subsets from melanoma patients following analog (ELA, n = 10) or native (EAA, n= 5) 
peptide vaccination, and from healthy individuals with EBV (n= 5) and/or CMV (n = 5) 
specific T-cells. B, Flow cytometry analysis of CD27, IL-7Rα, PD1, CD57, perforin and 
granzyme B expression was performed on bulk EM28pos and EM28neg CD8 T cells from the 
same tested samples as depicted in A, and Fig. 4, providing internal staining control.  
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Supplemental Figure 6. Tumor cell killing and efficiency of antigen recognition. Tumor-
specific T-cell clones were generated in vitro by limiting-dilution from blood samples 
corresponding to the same time-points after vaccination as those depicted in Fig. 1C. A, 
Complete data representing specific lysis of the Melan-A+ Me 290 tumor cell line in the 
absence of exogenous Melan-A peptide (10:1; effector:target ratio) by T-cell clones derived 
from EM28pos and EM28neg cells of patients vaccinated with analog peptide (grey whiskers) or 
native peptide (empty whiskers). B, The relative TCR avidity was compared using T2 target 
cells (A2+/TAP-/-) pulsed with graded concentrations of either analog (ELA) or native (EAA) 
Melan-A26-35 peptide. Complete data representing maximal lysis (upper panel) and EC50 (e.g. 
peptide concentration required to achieve 50% of maximal lysis; lower panel). Clones with 
undetectable lytic activity (EC50 > 10-6 M and/or maximal lysis < 20%) are symbolized as 
single dots above the y-axis to visualize them in the figures, and were not included in the 
statistical evaluations. * 0.01 < P < 0.001, ** 0.001 < P <0.0001, *** P < 0.0001 (two-tailed 
unpaired t test). 
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SUPPLEMENTAL METHODS 
 
Patients 
HLA-A2-positive patients with histological proven metastatic (stage III/IV) melanoma 
expressing Melan-A (RT-PCR or immuno-histochemistry) were included upon written 
informed consent, as described previously (1, 2). The following inclusion criteria had to be 
fulfilled: Karnofsky performance status of 70%, normal CBC and kidney-liver function, no 
concomitant anti-tumor therapy nor immunosuppressive drugs. Exclusion criteria were 
pregnancy, seropositivity for HIV-1 Ab or HBs Ag, brain metastases, uncontrolled bleeding, 
clinically significant autoimmune disease, and symptomatic heart disease (NYHA III-IV). 
Study end points were toxicity and CD8 T cell responses. 
 
Antibodies 
Extracellular and intracellular stainings were performed according to the manufacturer’s 
instructions. All FACS sorting experiments (ex vivo 5-cell and single-cell aliquots, and in 
vitro generation of T-cell clones) were performed using the following 5-color stain 
combination: (1) PE-HLA-A2/peptide multimers, (2) FITC-conjugated anti-CD28 (BD 
Pharmingen), (3) PE-Texas Red-conjugated anti-CD45RA (Beckman Coulter), (4) APC-Cy7-
conjugated anti-CD8 (BD Pharmingen) reagents and (5) anti-CCR7 mAb (BD Pharmingen) 
followed by APC-conjugated goat anti-rat IgG Ab (for indirect staining for CCR7) (Caltag 
Laboratories).  
Multi-parameter flow cytometry analyses were performed using the following 8-color stain 
strategy: (1) PE-HLA-A2/peptide multimers, (2) FITC-conjugated anti-CD57 (BD 
Pharmingen) or -PD1 (BD Pharmingen) or -Granzyme B (Hölzer Diagnostic) or –Perforin 
(Ancell), (3) PE-Texas Red-conjugated anti-CD45RA (Beckman Coulter), (4) PE-Cy7-
conjugated CCR7 (BD Pharmingen), (5) Alexafluor700 anti-CD28 (Biolegend), (6) Pacific 
Blue-labeled anti-CD8, (7) PerCP-Cy5.5 anti-CD127 (IL-7R) (Beckman Coulter), and (8) 
APC-eFluor780-conjugated anti-CD27 (eBioscience) mAbs. 
 
Direct cell lysis and cDNA synthesis 
Single-cell or five-cell aliquots were sorted by flow cytometry directly into 96-V bottom 
plates containing 15 µl of a lysis/cDNA mix solution supplemented with 1.2% Triton X-100 
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(Fluka), 30 µg/ml tRNA (Roche), 10 mM DTT (Fluka), 0.5 mM dNTP (Invitrogen, Paisley, 
UK), 2 ng/µl of a 20-mer oligo-dT (Amplimmun, Madulain, Switzerland), 4 U of RNAsin 
(Promega, Madison, WI), 3 µl of RT buffer (5x; Invitrogen) and 40 U of M-MLV 
transcriptase (Invitrogen), as described in detail elsewhere (1). To allow the transcription of 
total mRNA into cDNA, the 96-well plates were incubated 60 min at 37oC and briefly 
centrifuged and transferred into 0.5 ml PCR tubes. MMLV-RT transcriptase was inactivated 
at 90oC for 3 min and samples were stored at -80oC until further use. For T cell clones, 15 µl 
of lysis/cDNA mix was directly added to 105 cells and further processed as described above. 
 
Global cDNA amplification from single-cells 
The basic principle of the five-cell and single-cell global cDNA amplification protocol 
requires that the target sequences to be amplified be flanked by known sequences to which the 
amplification primers can anneal and initiate polymerization. One end is initially defined 
through a cDNA reaction using reverse transcriptase and an oligo(dT) primer that will prime 
via the poly(A) tail present at the 3’ end of most mRNA molecules. The other end is then 
created by the addition of an homopolymer d(A) sequence to the 3’-OH end of the first cDNA 
using terminal deoxynucleotidyl transferase. Global PCR amplification of the dA/dT flanked 
cDNAs is carried out using a single modified oligo(dT) primer as previously described by 
Brady and Iscove (4). Priming of the cDNA during global RT-PCR is initiated via annealing 
of the d(T) region of the 61-mer oligonucleotide primer to the homopolymeric d(A) regions 
present at the termini of the cDNA molecules. We have included a purification step before 
adding the poly d(A) tails, in order to get rid of free dNTPs that may interfere during the 
tailing reaction. Therefore, for further processing, cDNA from single-cell or five-cell aliquots 
were precipitated overnight at -20oC after addition of 7.5 µl of C2H7NO2 7.5 M (Fluka), 45 µl 
of ethanol 100% (Fluka) using 2 µl of Glycogen 10 mM (Roche) as carrier, washed in 150 µl 
of cold ethanol 70% and dried 1 hour at room temperature.  
To evaluate mRNA expression in small numbers of cells (1-10 cells), the following method 
was adapted from previously published protocols (4, 5). Briefly, to allow 3’oligo(dA) tailing 
to cDNA, the dried pellets were suspended in 5 µl of tailing solution containing 0.5 mM 
dATP (Amersham Pharmacia), 1 U of Terminal deoxynucleotidyl Transferase (Promega) and 
1 µl tailing buffer (5x; Promega) and incubated at 37oC for 30 min. After denaturation (94oC 
for 3 min), 45 µl of PCR-buffer (10 mM TRIS-HCl pH 8.8, 50 mM KCl, 0.1 mg/ml BSA, 2 
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mM MgCl2) containing 20 ng/µl of a 61-mer oligo dT (5’-CATGTCGTCCAGGCCGCTCTG 
GGACAAAATATGAATTCT23-3’) (Metabion), 0.2 mM dNTP, 0.5% Triton X-100, and 5 U 
Taq DNA recombinant polymerase Platinum (Invitrogen) were added, followed by 5 cycles of 
PCR (50s at 94oC; 2 min at 37oC; 9 min at 72oC) and of 35 cycles (50s at 94oC; 90s at 60oC; 8 
min at 72oC). 1 µl of amplified cDNA (also defined as cDNAplus) was then subjected to a 
second round of PCR amplification (38-40 cycles, 30s at 94oC; 45s at 58oC; 1 min at 72oC) in 
20 µl volumes of 1x PCR buffer containing 1.5 mM MgCl2, 0.2 mM dNTP, 0.5 U Taq 
Platinum and 40 ng of specific primers designed to amplify mRNA sequences of interest and 
the expected products were visualized after electrophoresis on a 1.2% agarose gel. Typically, 
we used H20 for the negative PCR control, while 103 PBMCs from a healthy individual was 
used as positive PCR control. 
 
Gene expression analysis 
For gene expression analysis of single cells, we used the following primers: CD3: 5’-
CGTTCAGTTCCCTCCTTTTCTT-3’; rev-5’-GATTAGGGGGTTGGTAGGGAGTG-3’, 
GAPDH: 5’- GGACCTGACCTGCCGTCTAG-3’; rev-5’-CCACCACCCTGTTGCTGTAG-
3’, CCR7: 5’-CCAGGCCTTATCTCCAAGACC-3’; rev-5’-GCATGTCATCCCCACTCTG-
3’, CD27: 5’-ACGTGACAGAGTGCCTTTTCG-3’; rev-5’-TTTGCCCGTCTTGTAGCATG-
3’, CD127/IL-7Ra: 5’-ATCTTGGCCTGTGTGTTATGG-3’; rev-5’-ATTCTTCTAGTTGCT 
GAGGAAACG-3’; CD94: 5’-GTGGGAGAATGGCTCTGCAC -3’; rev-5’-TGAGCTGTT 
GCTTACAGATATAACGA-3’, IFN-γ: 5’-GCCAACCTAAGCAAGATCCCA-3’; rev-5’-
GGAAGCACCAGGCATGAAATC-3’, Perforin: 5’-TTCACTGCCACGGATGCCTAT-3’; 
rev-5’-GCGGAATTTTAGGTGGCCA-3’, Granz B: 5’-GCAGGAAGATCGAAAGTGCGA-
3’; rev-5’-GCATGCCATTGTTTCGTCCAT-3’. 
 
TCR spectratyping, sequencing and clonotyping 
To rapidly identify TCR Vβ segment usage, a small fraction (5 µl of a total of 50 µl) from 10 
individually sorted and amplified 5-cell cDNA samples were pooled and subjected to 
individual PCR in non-saturating conditions using a set of previously validated fluorescent-
labeled forward primers specific for the 22 TCR Vβ subfamilies and one unlabeled reverse 
primer specific for the corresponding C gene segment (6, 7). This TCR Vβ-CDR3 
spectratyping analysis based on the equivalent of 50 cells represents a pre-screening step. 
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Once positive TCR Vβ subfamilies were identified, the following step consisted in subjecting 
each individually generated single-cell or 5-cell cDNA sample, and in parallel in vitro 
generated T cell clone to TCR Vβ PCRs. Separation and detection of amplified fragments that 
contain the entire CDR3 segment was performed in the presence of fluorescent size markers 
on an ABI PRISM 310 Genetic Analyzer (AppliedBiosystems, Rotkreuz, Switzerland) 
according to the manufacturer’s recommendations, and data were analyzed with GeneScan 
3.7.1 (AppliedBiosystems). In the last step, PCR products of interest were directly purified 
and sequenced from the reverse primer (Fasteris SA, Plan-les-Ouates, Switzerland). 
Clonotypic primers for several CDR3 sequences were validated and used in clonotypic PCR 
for determination of clonotype frequencies (unpublished data). 
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Supplemental Figure 1 
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 43 
Supplemental Figure 4 
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Supplemental Figure 6 
 
 
